Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Actinium Pharmaceuticals (NYSE MKT: ATNM) and Autolus Therapeutics (NASDAQ: AUTL)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPTResearch Report), Actinium Pharmaceuticals (ATNMResearch Report) and Autolus Therapeutics (AUTLResearch Report) with bullish sentiments.

Sarepta Therapeutics (SRPT)

In a report released today, Tim Lugo from William Blair maintained a Buy rating on Sarepta Therapeutics. The company’s shares closed last Monday at $135.65.

According to TipRanks.com, Lugo is a 5-star analyst with an average return of 13.3% and a 45.7% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $193.38, which is a 54.1% upside from current levels. In a report issued on December 2, H.C. Wainwright also assigned a Buy rating to the stock with a $160.00 price target.

See today’s analyst top recommended stocks >>

Actinium Pharmaceuticals (ATNM)

In a report issued on December 10, Andy Hsieh from William Blair reiterated a Buy rating on Actinium Pharmaceuticals. The company’s shares closed last Monday at $0.21, close to its 52-week low of $0.19.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 15.1% and a 62.1% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Seattle Genetics, and Beyondspring.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Actinium Pharmaceuticals with a $2.75 average price target, representing an 1122.2% upside. In a report issued on December 10, Maxim Group also maintained a Buy rating on the stock with a $1.50 price target.

Autolus Therapeutics (AUTL)

In a report issued on December 9, Matt Phipps from William Blair maintained a Buy rating on Autolus Therapeutics. The company’s shares closed last Monday at $12.72, close to its 52-week low of $9.50.

According to TipRanks.com, Phipps is ranked 0 out of 5 stars with an average return of -9.1% and a 45.5% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Atara Biotherapeutics.

Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $25.00, implying a 93.9% upside from current levels. In a report issued on December 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $24.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.